Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pan-Arctic Peatlands Have Expanded During Recent Warming.

Global change biology·2026
Same author

Erratum: First Search for Dyons with the Full MoEDAL Trapping Detector in 13 TeV pp Collisions [Phys. Rev. Lett. 126, 071801 (2021)].

Physical review letters·2024
Same author

In-person versus virtual administration of the American College of Rheumatology gold standard cognitive battery in systemic lupus erythematosus: Are they interchangeable?

Lupus·2023
Same author

Search for magnetic monopoles produced via the Schwinger mechanism.

Nature·2022
Same author

First Search for Dyons with the Full MoEDAL Trapping Detector in 13 TeV pp Collisions.

Physical review letters·2021
Same author

Cost-effectiveness of negative-pressure wound therapy in adults with severe open fractures of the lower limb: evidence from the WOLLF randomized controlled trial.

The bone & joint journal·2019

Related Experiment Video

Updated: May 7, 2026

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
09:40

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle

Published on: January 19, 2017

SLE and metabolic syndrome.

B Parker1, In Bruce

  • 11Arthritis Research UK Epidemiology Unit, Institute of Inflammation and Repair, Manchester Academic Health Sciences Centre, The University of Manchester, UK.

Lupus
|October 8, 2013
PubMed
Summary

Metabolic syndrome (MetS) is common in systemic lupus erythematosus (SLE) patients, increasing cardiovascular disease (CVD) risk. Identifying MetS aids targeted interventions and medication review to mitigate CVD risk in SLE.

Area of Science:

  • Rheumatology
  • Endocrinology
  • Cardiology

Background:

  • Metabolic syndrome (MetS) is a cluster of cardiovascular disease (CVD) risk factors linked to insulin resistance.
  • Systemic lupus erythematosus (SLE) patients exhibit a higher prevalence of MetS and insulin resistance.
  • Chronic inflammation and corticosteroid therapy in SLE may contribute to MetS development.

Purpose of the Study:

  • To explore the relationship between SLE and MetS.
  • To understand how SLE contributes to increased CVD risk.
  • To identify strategies for managing CVD risk in SLE patients with MetS.

Main Methods:

  • Observational study comparing MetS prevalence in SLE patients versus general population (implied).
  • Review of literature on inflammation, corticosteroids, and metabolic complications in SLE.
Keywords:
Systemic lupus erythematosusmetabolic syndrome

Related Experiment Videos

Last Updated: May 7, 2026

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
09:40

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle

Published on: January 19, 2017

  • Analysis of MetS as a model for CVD risk in SLE.

    • Main Results:

    • SLE patients have an increased prevalence of MetS and insulin resistance.
    • Both chronic inflammation and corticosteroid use are potential contributors to MetS in SLE.
    • MetS serves as a potential indicator for heightened CVD risk in SLE.

    Conclusions:

    • MetS is a significant concern in SLE, associated with increased CVD risk.
    • Identifying MetS in SLE patients allows for targeted lifestyle interventions.
    • Medication review, particularly corticosteroid doses, is crucial for managing CVD risk in SLE patients with MetS.